Cronos Group Inc.

TSX:CRON.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.57 -0.27%

-$0.01 today

Market cap
$1.67B
Beta
1.25
P/E (TTM)
-488.1
EPS (TTM)
-$0.01
52W Low $2.54High $4.66

Volume 0.15M

Average 0.19M

CRON.TO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Cronos Group Inc.TSX: CRON.TO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $44.47M rose 37.5% year over year, ahead of the +28.0% change in trailing-twelve-month revenue. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +19.4% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $226.69M (+52.0%) for the fiscal year ending Dec 2026, a step up from the +26.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$44.47M-1.7% QoQ
Last fiscal yearDec 2025
$149.15M+26.9% YoY
LTMMar 2026
$159.47M+28.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.5%+32.1%-5.4 pp
1 year+26.9%+52.0%+25.0 pp
3-year CAGR+19.4%+26.8%+7.4 pp
5-year CAGR+16.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
149.15M USD
Year-over-year change
+26.9%
4-year CAGR
+23.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CRON.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +28.0% is the 4th highest of 6, against a peer median of +31.1%.
  • Over three fiscal years its annual growth of +19.4% compares with a peer median of +11.8%.
CRON.TO Competitors
Revenue for CRON.TO and competitors
Company Period LTM YoY 3-year CAGR
EXE.TOExtendicare Inc.LTM Jun 2026CA$1.98B CAD+31.1%+10.8%
WELL.TOWELL Health Technologies Corp.LTM Mar 2026CA$1.47B CAD+50.1%+35.0%
SIA.TOSienna Senior Living Inc.LTM Sep 2026CA$1.11B CAD+14.9%+11.8%
TLRY.TOTilray Brands, Inc.LTM Feb 2026$858.28M USD+3.8%+9.3%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$510.45M CAD+36.9%+15.3%
CRON.TOCronos Group Inc.LTM Mar 2026$159.47M USD+28.0%+19.4%
Peer median (excluding CRON.TO) —+31.1%+11.8%

Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.02M87.54M87.03M117.5M149.15M
Cost of Revenue81.47M71.96M75.15M87.05M87.45M
Gross Profit(17.45M)15.58M11.88M30.45M61.7M
Gross Margin-27.3%17.8%13.7%25.9%41.4%
Research & Development21.66M13.25M5.83M4.22M4.53M
Selling, General & Admin120.67M101.64M80.74M76.74M75.01M
Operating Expenses272.09M128.01M96.48M106.91M79.54M
Depreciation & Amortization13.36M11.52M7.44M8.84M14.48M
EBITDA(150.79M)(93.81M)(72.28M)(45.37M)(2.94M)
EBITDA Margin-235.5%-107.2%-83.0%-38.6%-2.0%
Operating Income(289.54M)(112.44M)(84.6M)(76.46M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income8.92M21.84M52.07M49.52M40.66M
Interest Expense00000
Other Income / Expenses162.1M(9.66M)11.1M113.01M419.21K
Income Before Tax(127.44M)(122.1M)(73.49M)36.55M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(427.41K)34.48M(3.23M)(3.44M)(14.44M)
Net Income(392.81M)(170.26M)(73.79M)41.04M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(0.34)(0.42)(0.18)0.10(0.03)
EPS (Diluted)(0.34)(0.42)(0.18)0.10(0.03)
Weighted Avg Shares369.73M370.39M380.96M382.16M383.47M
Weighted Avg Shares (Diluted)370.39M370.39M380.96M382.16M383.47M

Cronos Group Inc.

TSX:CRON.TO

Intrinsic Alpha fair value

Locked

Current Price

$4.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.